Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 25, 2025
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
GlobeNewswire
·
March 25, 2025
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at …
NervGen Pharma to Host Virtual Investor Event
GlobeNewswire
·
March 25, 2025
VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it will host a virtual investor …
Central Lab Services Market worth US$8.18 billion by 2030 with 6.5% CAGR | MarketsandMarkets™
GlobeNewswire
·
March 25, 2025
Delray Beach, FL, March 25, 2025 (GLOBE NEWSWIRE) -- The global Central Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR of 6.5%, reaching US$5.97 billion in 2025 and an impressive US$8.18 billion by 2030. The …
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies
GlobeNewswire
·
March 25, 2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform optimized for solid tumor cancers, today …
Epilepsy Foundation of America Harnesses the “Power in Purple” for Special Awareness Day
GlobeNewswire
·
March 25, 2025
BOWIE, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Join the Epilepsy Foundation of America for Purple Day® on March 26, 2025 to uplift the “Power In Purple”, this year’s event theme. Approximately 65 million people are living with epilepsy across the world, …
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
·
March 25, 2025
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR …
TOMI Environmental Solutions, Inc. Partners with Pharma Biotech System Components to Enhance Disinfection Solutions
GlobeNewswire
·
March 25, 2025
FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and decontamination solutions, today announced an OEM partnership with Pharma Biotech System Components LLC/Pharma …
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
GlobeNewswire
·
March 25, 2025
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant …
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
GlobeNewswire
·
March 25, 2025
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: …
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
GlobeNewswire
·
March 25, 2025
Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering commitment to patient impact, “Breaking …
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
GlobeNewswire
·
March 25, 2025
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
GlobeNewswire
·
March 25, 2025
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to demonstrate an overall favorable safety profile Cassava’s …
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
GlobeNewswire
·
March 25, 2025
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Morningside Ventures Makes Strategic Investment in Xealth to Accelerate Digital Health Ecosystem
GlobeNewswire
·
March 25, 2025
BOSTON and SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Xealth, the leader in digital health enablement for health systems, today announced a strategic investment from Morningside Ventures, a leading investor in healthcare innovation. This investment will …
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
GlobeNewswire
·
March 25, 2025
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
GlobeNewswire
·
March 25, 2025
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's …
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
GlobeNewswire
·
March 25, 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International …
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
GlobeNewswire
·
March 25, 2025
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National …
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
GlobeNewswire
·
March 25, 2025
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared …
Richmond National Group, Inc. Announces Completion of Follow-On Equity Capital Raise
GlobeNewswire
·
March 25, 2025
RICHMOND, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Richmond National Group, Inc. and its affiliates (“Richmond National”) announced the successful closing of an oversubscribed equity capital raise. Richmond National, a specialty excess and surplus lines …